245 related articles for article (PubMed ID: 27839979)
1. Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.
Zimran A; Elstein D; Gonzalez DE; Lukina EA; Qin Y; Dinh Q; Turkia HB
Blood Cells Mol Dis; 2018 Feb; 68():153-159. PubMed ID: 27839979
[TBL] [Abstract][Full Text] [Related]
2. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement and substrate reduction therapy for Gaucher disease.
Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
Gonzalez DE; Turkia HB; Lukina EA; Kisinovsky I; Dridi MF; Elstein D; Zahrieh D; Crombez E; Bhirangi K; Barton NW; Zimran A
Am J Hematol; 2013 Mar; 88(3):166-71. PubMed ID: 23386328
[TBL] [Abstract][Full Text] [Related]
6. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
[TBL] [Abstract][Full Text] [Related]
7. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
[TBL] [Abstract][Full Text] [Related]
8. Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.
Hughes DA; Gonzalez DE; Lukina EA; Mehta A; Kabra M; Elstein D; Kisinovsky I; Giraldo P; Bavdekar A; Hangartner TN; Wang N; Crombez E; Zimran A
Am J Hematol; 2015 Jul; 90(7):584-91. PubMed ID: 25801797
[TBL] [Abstract][Full Text] [Related]
9. Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher disease.
Zimran A; Wang N; Ogg C; Crombez E; Cohn GM; Elstein D
Am J Hematol; 2015 Jul; 90(7):577-83. PubMed ID: 25903392
[TBL] [Abstract][Full Text] [Related]
10. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction.
Elstein D; Foldes AJ; Zahrieh D; Cohn GM; Djordjevic M; Brutaru C; Zimran A
Blood Cells Mol Dis; 2011 Jun; 47(1):56-61. PubMed ID: 21536468
[TBL] [Abstract][Full Text] [Related]
11. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.
Zimran A; Pastores GM; Tylki-Szymanska A; Hughes DA; Elstein D; Mardach R; Eng C; Smith L; Heisel-Kurth M; Charrow J; Harmatz P; Fernhoff P; Rhead W; Longo N; Giraldo P; Ruiz JA; Zahrieh D; Crombez E; Grabowski GA
Am J Hematol; 2013 Mar; 88(3):172-8. PubMed ID: 23339116
[TBL] [Abstract][Full Text] [Related]
13. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
[TBL] [Abstract][Full Text] [Related]
14. Velaglucerase alfa: a new option for Gaucher disease treatment.
Zimran A
Drugs Today (Barc); 2011 Jul; 47(7):515-29. PubMed ID: 22013559
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: Results after a cumulative treatment period of 24months.
Ida H; Tanaka A; Matsubayashi T; Murayama K; Hongo T; Lee HM; Mellgard B
Blood Cells Mol Dis; 2016 Jul; 59():140-7. PubMed ID: 27241455
[TBL] [Abstract][Full Text] [Related]
16. Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials.
Elstein D; Mellgard B; Dinh Q; Lan L; Qiu Y; Cozma C; Eichler S; Böttcher T; Zimran A
Mol Genet Metab; 2017 Sep; 122(1-2):113-120. PubMed ID: 28851512
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
Laudemann K; Moos L; Mengel E; Lollert A; Hoffmann C; Brixius-Huth M; Wagner D; Düber C; Staatz G
Blood Cells Mol Dis; 2016 Mar; 57():35-41. PubMed ID: 26852653
[TBL] [Abstract][Full Text] [Related]
18. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
Elstein D; Altarescu G; Maayan H; Phillips M; Abrahamov A; Hadas-Halpern I; Tiomkin M; Zimran A
Blood Cells Mol Dis; 2012 Jan; 48(1):45-50. PubMed ID: 22047948
[TBL] [Abstract][Full Text] [Related]
19. An observational study to investigate the relationship between plasma glucosylsphingosine (lyso-Gb1) concentration and treatment outcomes of patients with Gaucher disease in Japan.
Ida H; Watanabe Y; Sagara R; Inoue Y; Fernandez J
Orphanet J Rare Dis; 2022 Nov; 17(1):401. PubMed ID: 36329499
[TBL] [Abstract][Full Text] [Related]
20. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
Elstein D; Cohn GM; Wang N; Djordjevic M; Brutaru C; Zimran A
Blood Cells Mol Dis; 2011 Jan; 46(1):119-23. PubMed ID: 20727796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]